Vasoactive Intestinal Peptide (VIP): The Neuropeptide Regulator of Inflammation, Immunity, and Neural Function

Discovery and Background

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide first isolated from porcine small intestine in 1970 by Sami Said and Viktor Mutt at the Karolinska Institute. Its name reflects the initial observation that prompted its discovery: upon injection, the peptide produced dramatic vasodilation and a drop in systemic blood pressure — effects striking enough to define it as a distinct vasoactive compound. What was not apparent from that first characterization was the extraordinary breadth of biological roles VIP would eventually be found to occupy.

VIP belongs to the glucagon/secretin superfamily of peptides and is structurally related to pituitary adenylate cyclase-activating polypeptide (PACAP), secretin, and glucagon. It is produced throughout the body — in neurons of the central and peripheral nervous systems, in immune cells, and in epithelial cells of the lung, gut, and reproductive organs — and acts through three G protein-coupled receptors: VPAC1, VPAC2, and PAC1. This wide distribution of both the peptide and its receptors reflects VIP's role not as a narrow hormonal signal but as a broad-spectrum regulatory molecule coordinating communication between the nervous, immune, and endocrine systems.

Research into VIP expanded rapidly through the 1980s and 1990s as investigators recognized its presence throughout the enteric nervous system, its role in circadian rhythm regulation via the suprachiasmatic nucleus, and its potent suppression of inflammatory immune responses. The intersection of all three areas — gut, brain, and immune regulation — positioned VIP as a compound of unusual integrative importance. More recently, interest has intensified around its potential therapeutic role in conditions ranging from pulmonary arterial hypertension and inflammatory bowel disease to autism spectrum disorder and long COVID, where dysregulation of VIP signaling has been implicated as a contributing mechanism.

Research Overview

The most advanced clinical evidence for VIP as a therapeutic agent comes from pulmonary research. Inhaled VIP was investigated in human trials for pulmonary arterial hypertension, where it demonstrated meaningful reductions in pulmonary vascular resistance and improvements in exercise capacity in early studies. A landmark finding in this area was the observation that patients with idiopathic pulmonary arterial hypertension show a near-complete absence of VIP immunoreactivity in lung tissue compared to healthy controls, suggesting VIP deficiency may be pathogenic rather than merely correlative.

In inflammatory and autoimmune disease, preclinical evidence is extensive. VIP has demonstrated protective effects in animal models of rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, sepsis, and type 1 diabetes — consistently acting to suppress Th1 and Th17 pro-inflammatory responses while promoting regulatory T-cell (Treg) differentiation and tolerogenic dendritic cell function. A synthetic VIP analog, aviptadil, has been investigated in human trials for acute respiratory distress syndrome (ARDS) and severe COVID-19 pneumonia, with Phase II data showing reductions in mortality and inflammatory markers in critically ill patients.

Neurological research has highlighted VIP's role in neuroprotection and circadian function. VIP-expressing neurons in the suprachiasmatic nucleus are central pacemakers of the circadian clock, and disruption of VIP signaling produces fragmented and dysrhythmic circadian output with downstream effects on sleep, metabolism, and immune timing. In neurodegenerative contexts, VIP reduces neuroinflammation, supports neuronal survival under oxidative stress, and promotes the clearance of amyloid-beta in preclinical Alzheimer's models, placing it at the intersection of inflammation biology and neurodegeneration research.

Clinical awareness of VIP deficiency as a systemic pathological state has grown through the work of researchers studying chronic inflammatory response syndrome (CIRS) — a condition associated with biotoxin exposure, particularly mold-related illness — in which VIP levels are consistently and severely depressed. Intranasal VIP has been used therapeutically in this context with reported improvements in fatigue, cognitive function, pulmonary resistance, and inflammatory markers, forming a clinical use case that has attracted significant attention in functional and integrative medicine.

Key Mechanisms

VPAC Receptor Signaling and cAMP Elevation

VIP exerts most of its effects through VPAC1 and VPAC2 receptors, both of which couple to Gs proteins and activate adenylate cyclase, raising intracellular cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA) and the transcription factor CREB, producing broad downstream effects on gene expression, cell survival, and inflammatory regulation. VPAC1 is constitutively expressed on most immune and epithelial cells, while VPAC2 expression is more inducible and tissue-specific, allowing VIP to modulate both baseline and stimulus-driven responses depending on the cellular context.

Immune Tolerance and Regulatory T-Cell Induction

VIP is one of the most potent endogenous inducers of immune tolerance known. It promotes the differentiation of naive T-cells toward the regulatory T-cell (Treg) phenotype while suppressing differentiation into Th1 and Th17 effector subsets. It simultaneously drives dendritic cells toward a tolerogenic state, reducing their production of IL-12 and IL-23 — the cytokines that fuel pro-inflammatory adaptive responses — while increasing IL-10 production. The net effect is a shift in immune tone from reactive and inflammatory toward tolerant and regulatory, which is mechanistically relevant to autoimmune disease, chronic inflammation, and immune senescence.

NF-kB Suppression and Anti-Inflammatory Gene Regulation

VIP directly inhibits NF-kB activation in macrophages, dendritic cells, and epithelial cells, reducing transcription of pro-inflammatory genes encoding TNF-alpha, IL-1beta, IL-6, and inducible nitric oxide synthase (iNOS). This suppression of the central inflammatory transcription factor is complemented by upregulation of anti-inflammatory mediators including IL-10 and TGF-beta, creating a coordinated shift in the inflammatory gene expression program. VIP's ability to act at the transcriptional level makes its anti-inflammatory effects durable and broadly applicable across tissue types.

Pulmonary Vasodilation and Airway Protection

VIP is a potent dilator of pulmonary vasculature and bronchial smooth muscle, acting through cAMP-mediated relaxation of vascular and airway smooth muscle cells. In the lung, it inhibits the proliferation of pulmonary artery smooth muscle cells — the process that drives pathological vascular remodeling in pulmonary hypertension — and protects alveolar epithelial cells from inflammatory and oxidative damage. Its near-absence from the lungs of pulmonary arterial hypertension patients underscores the extent to which endogenous VIP normally restrains the vascular remodeling that drives this disease.

Circadian Rhythm Coordination

VIP-producing neurons in the suprachiasmatic nucleus (SCN) synchronize the firing patterns of individual clock cells into a coherent whole-body circadian rhythm. VIP released by these neurons acts on neighboring SCN cells via VPAC2 receptors, coupling their molecular clocks and enabling the SCN to function as a unified pacemaker rather than a collection of independent oscillators. When VIP signaling is disrupted — whether by genetic deletion in animal models or by inflammatory conditions in humans — the circadian system fragments, with cascading consequences for sleep architecture, hormonal rhythms, metabolic timing, and immune function.

Neuroprotection and Neuroinflammation Suppression

VIP protects neurons from excitotoxic, oxidative, and inflammatory injury through multiple complementary mechanisms: suppression of microglial activation, reduction of nitric oxide overproduction, upregulation of neurotrophic factors including BDNF and PACAP, and direct promotion of neuronal survival signaling via PI3K/Akt pathways. In models of Alzheimer's disease, Parkinson's disease, and multiple sclerosis, VIP administration consistently reduces neuroinflammation and slows disease progression, supporting its potential as a neuroprotective agent in conditions where chronic neuroinflammation drives pathology.

Common Applications

Pulmonary Arterial Hypertension

VIP deficiency in lung tissue has been documented in idiopathic pulmonary arterial hypertension, and inhaled VIP has been investigated as a direct replacement strategy. Early human trials demonstrated improvements in pulmonary vascular resistance and exercise tolerance, positioning inhaled VIP as a mechanistically rational intervention in a disease area where treatment options remain limited and prognosis is poor. This remains one of the most clinically developed therapeutic applications for VIP.

Autoimmune and Chronic Inflammatory Disease

VIP's ability to shift immune tone toward tolerance and suppress Th1/Th17-driven inflammation makes it a compelling candidate for autoimmune conditions including rheumatoid arthritis, inflammatory bowel disease, psoriasis, and multiple sclerosis. Preclinical evidence across all of these indications is robust, and the development of stable VIP analogs and delivery systems has advanced translational prospects. In integrative practice, intranasal and systemic VIP are used as part of protocols targeting chronic inflammatory dysregulation.

Severe Infection and ARDS

Aviptadil, a synthetic VIP analog, has been investigated in clinical trials for COVID-19-associated ARDS and respiratory failure, with Phase II data reporting reduced mortality in critically ill patients alongside reductions in IL-6 and other inflammatory markers. This builds on earlier preclinical evidence showing VIP's ability to protect alveolar epithelial cells from inflammatory destruction and to suppress the cytokine overproduction that drives respiratory failure in severe infection — an application where VIP's dual anti-inflammatory and pulmonary-protective mechanisms are directly relevant.

Chronic Inflammatory Response Syndrome (CIRS)

In the context of biotoxin-associated illness — particularly mold-related CIRS — VIP deficiency is a recognized and measurable feature of the condition, contributing to pulmonary restriction, cognitive impairment, fatigue, and dysregulated inflammation. Intranasal VIP has been used therapeutically in CIRS protocols developed by researchers including Ritchie Shoemaker, with reported improvements across multiple domains including pulmonary function, inflammatory biomarkers, and cognitive performance. This represents one of the more developed clinical use cases for VIP in functional and integrative medicine.

Cognitive Function and Neurological Support

VIP's neuroprotective, anti-neuroinflammatory, and circadian-regulatory effects position it as a compound of interest for cognitive longevity and neurological resilience. Its role in SCN-mediated circadian coordination has direct implications for sleep quality, hormonal regulation, and the metabolic health consequences of circadian disruption. In neurodegenerative contexts, its suppression of microglial activation and promotion of neuronal survival signaling addresses mechanisms increasingly understood to drive Alzheimer's and Parkinson's pathology.

Longevity and Systemic Inflammation Management

VIP's convergent effects on immune aging, circadian regulation, neuroinflammation, and vascular health make it relevant to comprehensive longevity protocols. Chronic low-grade inflammation — driven by aging immune cells, deteriorating circadian function, and accumulating senescent cells — is a central mechanism of biological aging, and VIP addresses this axis through multiple complementary pathways. It is used in longevity-focused clinical practice, typically via intranasal administration, as part of protocols targeting inflammaging, immune dysregulation, and cognitive preservation.

References

1. https://pubmed.ncbi.nlm.nih.gov/4917691/
2. https://pubmed.ncbi.nlm.nih.gov/15546761/
3. https://pubmed.ncbi.nlm.nih.gov/17418467/
4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2128029/
5. https://pubmed.ncbi.nlm.nih.gov/12165551/
6. https://pubmed.ncbi.nlm.nih.gov/16037386/
7. https://pubmed.ncbi.nlm.nih.gov/33390186/
8. https://pubmed.ncbi.nlm.nih.gov/20564087/
9. https://www.frontiersin.org/articles/10.3389/fendo.2019.00524/full
10. https://pubmed.ncbi.nlm.nih.gov/25178848/

Note: This list compiles unique sources referenced throughout the article. For a full bibliography, including additional studies mentioned in the content, consult the original research compilations or databases like PubMed.